Trials / Completed
CompletedNCT00446797
Open Label Comparative Study On Celecoxib Efficacy And Safety Vs Non-Selective NSAID In Acute Pain Due To Ankle Sprain
An Open Label Randomized Multicenter Comparative Study On Celecoxib Efficacy And Safety Versus Non-Selective NSAID In Acute Pain Due To Ankle Sprain
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 278 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy of celecoxib loading dose of 400mg followed by 200 mg twice a day (BID) versus oral non-selective NSAIDs in acute pain due to ankle sprain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Non-selective NSAIDS | Non-selective NSAIDs administered at usual (standard) doses. |
| DRUG | Celecoxib | celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days. |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
- First posted
- 2007-03-13
- Last updated
- 2021-02-21
- Results posted
- 2009-06-10
Locations
16 sites across 8 countries: Brazil, Costa Rica, Ecuador, Egypt, Jordan, Mexico, Panama, Peru
Source: ClinicalTrials.gov record NCT00446797. Inclusion in this directory is not an endorsement.